BioMark Diagnostics Inc, an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, has announced several updates from ongoing clinical trial using the company's liquid biopsy test for early cancer detection and monitoring of lung cancer.
As clinical trial success relies on effective patient recruitment, BioMark announced that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year. The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Qu
